Search Within

Heiko Schoder

  1. "Population Sciences Research Program"
Formats
  1. Meeting Abstract (29)
  2. Journal Article (24)
  3. Research Letter (1)
Groups
  1. Department of Medicine (54)
  2. Molecular Imaging and Therapy Service (54)
  3. Population Sciences Research Program (54)
  4. Radiology, Department of (54)
  5. Hematologic Malignancies, Division of (53)
  6. Center for Hematologic Malignancies (52)

More Groups

People
  1. Steven Horwitz (49)
  2. Andrew Zelenetz (43)
  3. Alison Moskowitz (41)
  4. Paul Hamlin (41)
  5. Ariela Noy (39)
  6. Maria Palomba (38)

More People

Years
  1. 2025 (2)
  2. 2024 (4)
  3. 2023 (5)
  4. 2022 (4)
  5. 2021 (8)
  6. 2020 (4)

More Years

Publications
  1. Blood (22)
  2. Journal of Clinical Oncology (7)
  3. Hematological Oncology (5)
  4. Leukemia and Lymphoma (3)
  5. Annals of Oncology (2)
  6. Blood Advances (2)

More Publications

Publishers
  1. American Society of Hematology (24)
  2. American Society of Clinical Oncology (7)
  3. Wiley Blackwell (5)
  4. Nature Publishing Group (3)
  5. Taylor & Francis Group (3)
  6. Ferrata Storti Foundation (2)

More Publishers

Results (54)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The geriatric syndrome of sarcopenia impacts allogeneic hematopoietic cell transplantation outcomes in combination with multi-morbidity and functional impairment
    Meeting Abstract

    Lin, R. J.; Michaud, L.; Lobaugh, S. M.; Nakajima, R.; Elko, T. A.; Ruiz, J. D.; Sauter, C. S.; Dahi, P. B.; Maloy, M. A.; Perales, M. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin combined with AVD chemotherapy and radiotherapy in patients with newly diagnosed early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L. E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S.; Drill, E.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma
    Journal Article

    Mehta-Shah, N.; Ito, K.; Bantilan, K.; Moskowitz, A. J.; Sauter, C.; Horwitz, S. M.; Schöder, H.
    Blood Advances (2019)

    Fulltext@MSK | Save
  • Phase I dose escalation of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL)
    Meeting Abstract

    Batlevi, C. L.; Hamlin, P. A.; Matasar, M. J.; Horwitz, S. M.; Gerecitano, J. F.; Moskowitz, C. H.; Straus, D. J.; Zelenetz, A. D.; Drullinsky, P.; Copeland, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Chen, R. W.; Constine, L. S.; Courtien, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Phase I/IB dose escalation and expansion of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma
    Meeting Abstract

    Batlevi, C.; Hamlin, P.; Matasar, M.; Gerecitano, J.; Drullinsky, P.; Hamilton, A.; Straus, D.; Horwitz, S.; Kumar, A.; Moskowitz, C.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Interim PET evaluation by Deauville criteria is an effective risk stratification tool in PTCL
    Meeting Abstract

    Mehta-Shah, N.; Ito, K.; Bantilan, K. S.; Moskowitz, A. J.; Sauter, C. S.; Horwitz, S. M.; Schoder, H.
    Blood (2016)

    Fulltext@MSK | Save
  • PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma - Lack of Improvement with 3 versus 2 cycles of weekly brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Haematologica (2016)

    Fulltext@MSK | Save